Praxis Precision Medicines Inc. (PRAX) News
Filter PRAX News Items
PRAX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PRAX News From Around the Web
Below are the latest news stories about PRAXIS PRECISION MEDICINES INC that investors may wish to consider to help them evaluate PRAX as an investment opportunity.
Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to TradeThe mean of analysts' price targets for Praxis Precision Medicines, Inc. (PRAX) points to a 495% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming MeetingsBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting, |
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare ConferenceBOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast throug |
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesBOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental a |
Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Praxis Precision Medicines, Inc. (PRAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Praxis Precision Medicines Inc (PRAX) Reports Q3 2023 Financial ResultsCompany's Cash Position Supports Runway into Q1 2025, R&D Expenses Decrease by 43.5% Year-Over-Year |
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsEssential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development Cash of $101.1 million as of September 30, 2023 supports runway into Q1 2025 BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CN |
Praxis Precision Medicines to Present at Truist Securities BioPharma SymposiumBOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a panel discussion titled “CNS Companies Looking To Address High Unmet High Prevalence and High Value Diseases” at the Truist Securities BioPharma Sy |
Praxis Precision Medicines Stock Down 11% But Insiders Still In US$62k ProfitPraxis Precision Medicines, Inc. ( NASDAQ:PRAX ) insiders who acquired shares over the previous 12 months, can probably... |